欧林生物(688319) - 投资者关系活动记录表

Financial Performance - In 2023, the company achieved a revenue of 496.12 million yuan, a year-on-year decrease, with a net profit attributable to shareholders of 17.56 million yuan, down 33.94% [3] - In Q1 2024, the company reported a revenue of 70.80 million yuan, a year-on-year increase of 5.87%, but a net loss of 25.99 million yuan due to increased R&D expenses [4] Product Development - As of mid-April 2024, over 3,000 cases have been enrolled in the Phase III clinical trial for the recombinant pneumococcal vaccine, with enrollment progress exceeding 50% [5] - The company plans to increase the number of clinical trial hospitals to over 60 to expedite enrollment [5] Market Strategy - The company aims to enhance market access and academic promotion to increase the penetration rate of the adsorbed tetanus vaccine in hospitals [7] - Plans are in place to submit a Pre-IND application for the trivalent influenza vaccine to adapt to WHO recommendations [7] Risk Management - Investors are advised to be aware of the uncertainties related to the clinical trial progress and market conditions for vaccine products [4][6] - The company emphasizes the importance of understanding the risks associated with vaccine development and market competition [6]